Physician Views Preview: How will European dermatologists use Rinvoq in AD?

AbbVie's oral JAK inhibitor Rinvoq may be stuck in something of a regulatory holding pattern in the US, but in Europe has been recommended for approval as a treatment for atopic dermatitis (AD).

Our latest Physician Views poll seeks further clarity from dermatologists as to how they might use Rinvoq and what competition it could pose to Sanofi and Regeneron Pharmaceuticals' Dupixent in the AD market.

We are asking European dermatologists…

  • Do you intend to prescribe Rinvoq for moderate-to-severe atopic dermatitis in adult patients?
  • Do you intend to prescribe Rinvoq for moderate-to-severe atopic dermatitis in adolescent patients?
  • How would you best describe your level of knowledge about the efficacy and safety profile of Rinvoq and other JAK inhibitors as potential treatment for moderate-to-severe atopic dermatitis?
  • Overall, in what type of patients do you think most Rinvoq use will occur?
  • Do you think Rinvoq's efficacy profile or its once-daily oral dosing will be a bigger motivation of future use?

Survey results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here

To read more Physician Views articles, click here.